[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642492":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":28,"locations":35,"responsibleParty":55,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":24,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"All India Institute of Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Fractionated Chemoradiation","ACTIVE_COMPARATOR","Standard fractionated chemoradiation consisting of external beam radiotherapy to 45 Gy in 25 fractions delivered in conventional daily fractions over 5 weeks, concurrent weekly cisplatin, and brachytherapy to 700 cGy in 4 fractions.",[13],"Radiation: Standard fractionated chemoradiation",{"label":15,"type":16,"description":17,"interventionNames":18},"Hypofractionated Chemoradiation","EXPERIMENTAL","Hypofractionated chemoradiation consisting of external beam radiotherapy to 37.5 Gy in 15 fractions over approximately 3 weeks, concurrent weekly cisplatin, and brachytherapy to 700 cGy in 4 fractions.",[19],"Radiation: Hypofractionated Chemoradiation",[21,25],{"type":22,"name":15,"description":17,"armGroupLabels":23,"otherNames":24},"RADIATION",[15],null,{"type":22,"name":26,"description":11,"armGroupLabels":27,"otherNames":24},"Standard fractionated chemoradiation",[9],[29],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Karun Kamboj, MD - Radiation Oncology","CONTACT","9416613389","4122","karunkamboj04@aiims.edu",[36],{"facility":37,"status":38,"city":39,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India","RECRUITING","New Delhi","110029","India","IN",{"type":44,"coordinates":45},"Point",[46,47],77.2148,28.62137,{"lat":47,"lon":46},[50,52,53],{"name":51,"role":31,"phone":32,"phoneExt":24,"email":34},"Karun Kamboj, MD",{"name":24,"role":31,"phone":24,"phoneExt":24,"email":34},{"name":51,"role":54,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Karun Kamboj","Assistant Professor",[59],{"name":60,"class":61},"Varian, a Siemens Healthineers Company","INDUSTRY","100642492","hypofractionated-radiotherapy-in-cervical-cancer-100642492",false,"NCT07625943","HYPOfractionated RadioTherapy in Cervical Cancer","Hypofractionated Radiotherapy in Cervical Cancer: A Non-inferiority Randomized Controlled Trial","HYPORT-CC","Inclusion Criteria:\n\nFemale participants aged 18 to 65 years.\n\nHistopathologically confirmed cervical cancer.\n\nFIGO stage IB3 to IIIC1.\n\nSuitable for definitive concurrent chemoradiation.\n\nECOG performance status 0 to 2.\n\nAdequate hematological, renal, and hepatic function.\n\nAble and willing to provide informed consent.\n\nExclusion Criteria:\n\nECOG performance status 3 or higher.\n\nFIGO stage IIIC2, IVA, or IVB.\n\nPrior pelvic radiotherapy or prior chemotherapy for cervical cancer.\n\nInflammatory bowel disease.\n\nHydronephrosis.\n\nPregnancy.\n\nSynchronous malignancy.\n\nAny serious medical condition that would interfere with protocol treatment or follow-up.","FEMALE","18 Years","65 Years",{"count":74,"type":75},396,"ESTIMATED","INTERVENTIONAL",[78],"NA","The study is a prospective, randomized, non-inferiority clinical trial which will test whether a short course of radiation treatment (hypofractionation) for cervical cancer works as well as the standard longer course. Cervical cancer is one of the most common cancers in women in India, and many patients have trouble completing treatment because it takes several weeks and requires many hospital visits.\n\nIn this trial, females with locally advanced cervical cancer will be randomly assigned to one of two treatment groups. One group will receive the standard radiation schedule with External Beam RadioTherapy (EBRT) over about 5 weeks, weekly cisplatin chemotherapy, and brachytherapy. The other group will receive a shorter, hypofractionated external beam radiotherapy schedule over about 3 weeks, the same chemotherapy, and brachytherapy.\n\nResearchers will compare the two groups to see whether the hypofractionated schedule is non-inferior to the standard radiation therapy schedule. The main outcomes will be tumor control in the pelvis, side effects, survival, and quality of life. If the hypofractionated schedule meets the non-inferiority limit, it could reduce treatment time, improve patient convenience, and help more people receive treatment in busy cancer centers in emerging countries.",[81,82],"Cervical Cancer Squamous Cell","Cervical Cancer",[84,85,86,87,88],"cervical cancer","chemoradiation","hypofractionation","brachytherapy","external beam radiotherapy","2026-06-12",{"date":91,"type":92},"2026-06-16","ACTUAL",{"date":94,"type":92},"2026-01-15",{"date":96,"type":75},"2030-01-30",{"name":5,"class":6},1]